Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients – Randomised Controlled Trial
2024-519024-25-00Phase 2Authorised
- Sponsor
- Faculty Hospital Kralovske Vinohrady
- Start
- Dec 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in antibiotic-associated diarrhea (AAD) comparing Faecal bacteriotherapy arm with Control arm (standard of care) (2 arms). Primary endpoint: Treatment failure at day 7. Planned start Dec 2024; status: authorised.
02
Drugs
allogeneic pooled human faecal microbiota transplant
03
Conditions
antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on 2024-519024-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519024-25-00.